Segment Information - Schedule of Significant Segment Expenses (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Segment Reporting [Line Items] | |||||
| Total revenues | $ 3,333.9 | $ 2,964.7 | $ 6,320.8 | $ 5,734.9 | |
| Cost of sales | 489.2 | 407.5 | 882.0 | 770.5 | |
| Acquired in-process research and development expenses | 21.4 | 2.2 | 21.9 | 22.0 | |
| Intangible asset impairment charge | 0.0 | 0.0 | $ 379.0 | 0.0 | 379.0 |
| Interest income, net | (120.6) | (118.7) | (235.4) | (236.6) | |
| Provision for income taxes | 292.0 | 250.1 | 513.5 | 334.2 | |
| Net income | 1,099.8 | 1,032.9 | 2,131.2 | 1,679.2 | |
| Pharmaceuticals | |||||
| Segment Reporting [Line Items] | |||||
| Total revenues | 3,333.9 | 2,964.7 | 6,320.8 | 5,734.9 | |
| Research expenses | 207.3 | 209.3 | 412.3 | 415.4 | |
| Development expenses | 786.5 | 769.1 | 1,543.1 | 1,542.7 | |
| Acquired in-process research and development expenses | 21.4 | 2.2 | 21.9 | 22.0 | |
| Selling and other commercial expenses | 388.1 | 264.6 | 701.7 | 505.7 | |
| General and administrative expenses | 194.1 | 160.0 | 374.2 | 315.3 | |
| Intangible asset impairment charge | 0.0 | 0.0 | 0.0 | 379.0 | |
| Interest income, net | (120.6) | (118.7) | (235.4) | (236.6) | |
| Other segment items | (23.9) | (12.3) | (23.7) | 7.5 | |
| Provision for income taxes | 292.0 | 250.1 | 513.5 | 334.2 | |
| Net income | 1,099.8 | 1,032.9 | 2,131.2 | 1,679.2 | |
| Products | |||||
| Segment Reporting [Line Items] | |||||
| Total revenues | 3,333.9 | 2,944.0 | 6,320.8 | 5,704.2 | |
| Products | Pharmaceuticals | |||||
| Segment Reporting [Line Items] | |||||
| Cost of sales | 218.3 | 140.5 | 378.5 | 271.1 | |
| Royalty | Pharmaceuticals | |||||
| Segment Reporting [Line Items] | |||||
| Cost of sales | $ 270.9 | $ 267.0 | $ 503.5 | $ 499.4 | |
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of impairment loss for indefinite-lived intangible asset. Excludes goodwill. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. Includes, but is not limited to, software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Expenses recognized in the period that are directly related to the selling and distribution of products or services. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Development Expenses No definition available.
|
| X | ||||||||||
- Definition Research Expenses No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|